KR102377007B1 - 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 융합 피리미딘 골격 설폰아마이드 유도체 - Google Patents

상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 융합 피리미딘 골격 설폰아마이드 유도체 Download PDF

Info

Publication number
KR102377007B1
KR102377007B1 KR1020190098931A KR20190098931A KR102377007B1 KR 102377007 B1 KR102377007 B1 KR 102377007B1 KR 1020190098931 A KR1020190098931 A KR 1020190098931A KR 20190098931 A KR20190098931 A KR 20190098931A KR 102377007 B1 KR102377007 B1 KR 102377007B1
Authority
KR
South Korea
Prior art keywords
growth factor
factor receptor
epidermal growth
receptor inhibitor
sulfonamide derivative
Prior art date
Application number
KR1020190098931A
Other languages
English (en)
Other versions
KR20200033725A (ko
Inventor
장선영
김미라
전지영
곽은주
이선회
Original Assignee
한미약품 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한미약품 주식회사 filed Critical 한미약품 주식회사
Priority to EP19862042.9A priority Critical patent/EP3842435A4/en
Priority to CN201980062074.9A priority patent/CN112739701B/zh
Priority to US17/278,017 priority patent/US20210380589A1/en
Priority to PCT/KR2019/012207 priority patent/WO2020060268A1/ko
Publication of KR20200033725A publication Critical patent/KR20200033725A/ko
Application granted granted Critical
Publication of KR102377007B1 publication Critical patent/KR102377007B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
KR1020190098931A 2018-09-20 2019-08-13 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 융합 피리미딘 골격 설폰아마이드 유도체 KR102377007B1 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP19862042.9A EP3842435A4 (en) 2018-09-20 2019-09-20 NEW SULFONAMIDE DERIVATIVE PRESENTING A FUSED PYRIMIDINE SKELETON, HAVING AN INHIBITOR EFFECT OF EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION
CN201980062074.9A CN112739701B (zh) 2018-09-20 2019-09-20 具有表皮生长因子受体突变的抑制效果的融合嘧啶骨架磺酰胺衍生物
US17/278,017 US20210380589A1 (en) 2018-09-20 2019-09-20 Novel sulfonamide derivative with fused pyrimidine skeleton, having epidermal growth factor receptor mutation inhibitory effect
PCT/KR2019/012207 WO2020060268A1 (ko) 2018-09-20 2019-09-20 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 융합 피리미딘 골격 설폰아마이드 유도체

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180113083 2018-09-20
KR1020180113083 2018-09-20

Publications (2)

Publication Number Publication Date
KR20200033725A KR20200033725A (ko) 2020-03-30
KR102377007B1 true KR102377007B1 (ko) 2022-03-22

Family

ID=70003429

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020190098931A KR102377007B1 (ko) 2018-09-20 2019-08-13 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 융합 피리미딘 골격 설폰아마이드 유도체

Country Status (3)

Country Link
US (1) US20210380589A1 (ko)
KR (1) KR102377007B1 (ko)
CN (1) CN112739701B (ko)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102093364B (zh) * 2011-01-07 2015-01-28 北京赛林泰医药技术有限公司 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
CN102816162B (zh) * 2011-06-10 2016-04-27 中国科学院广州生物医药与健康研究院 嘧啶并嘧啶酮类化合物及其药用组合物和应用
JP5914667B2 (ja) * 2011-09-22 2016-05-11 ファイザー・インク ピロロピリミジンおよびプリン誘導体
CN105884695B (zh) * 2015-02-13 2019-02-26 山东轩竹医药科技有限公司 杂环衍生物类酪氨酸激酶抑制剂
CN106188060A (zh) * 2015-04-29 2016-12-07 厦门大学 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用
WO2017066428A1 (en) * 2015-10-13 2017-04-20 H. Lee Moffitt Cancer Center & Research Institute, Inc. Brd4-kinase inhibitors as cancer therapeutics
CN110691782A (zh) * 2016-12-01 2020-01-14 艾普托斯生物科学公司 作为brd4和jak2双重抑制剂的稠合的嘧啶化合物及其使用方法
AU2018341599A1 (en) * 2017-09-28 2020-04-09 Metabolon, Inc. Compounds, reagents, and uses thereof
KR101992621B1 (ko) * 2017-12-07 2019-09-27 주식회사 온코빅스 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물
WO2019112344A1 (ko) * 2017-12-07 2019-06-13 주식회사 온코빅스 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
KR20200033725A (ko) 2020-03-30
CN112739701B (zh) 2024-02-13
CN112739701A (zh) 2021-04-30
US20210380589A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
EP3399968B8 (en) Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
IL251818B (en) Crystal forms of 5-chloro-ene 4-[2-(dimethylphosphoryl)phenyl]-ene2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidine-2- 4-diamine
EP3548496A4 (en) PYRIMIDINE COMPOUNDS FUSED AS DUAL INHIBITORS OF BRD4 AND JAK2 AND METHODS OF USE THEREOF
EP3648753A4 (en) SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF EGFR TYROSINE KINASE
IL277455A (en) History of aminopyrimidines as CTPS1 inhibitors
PT3433253T (pt) Compostos de pirimidina como inibidores de jak cinases
IL279101A (en) Salts of spiafatrin are accepted in pharmacies
HK1246667A1 (zh) 作為jak抑制劑的2-(吡唑並吡啶-3-基)嘧啶衍生物
SG11202103823PA (en) Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors
EP3755311A4 (en) USEFUL INDANE-AMINES AS AN AGONISTS OF PD-L1
HUE060401T2 (hu) Pirimidin vegyület, mint JAK kináz inhibitor
EP3814341A4 (en) ERBB RECEPTOR INHIBITORS
PT3569793T (pt) Peça de nivelamento para ladrilhos de revestimento
EP3860627A4 (en) METHODS OF EXPANSION OF MESENCHYMAL STROM CELLS
SG11202107680PA (en) Novel substituted sulfonylurea derivatives
EP3686199A4 (en) CONDENSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR
EP3774813A4 (en) PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES USED AS AN A2A RECEPTOR ANTAGONIST
EP3911323A4 (en) HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
EP3693365A4 (en) EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS
IL304450A (en) New pyrimidin-2-yl sulfonamide derivatives
EP3661919A4 (en) SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS AND USES THEREOF
SG11202102015QA (en) Fused ring derivative used as fgfr4 inhibitor
EP3313396A4 (en) G-PROTEIN-COUPLED RECEPTOR CINASE INHIBITORS AND METHOD OF USE THEREOF
MX2017008430A (es) Métodos para preparar derivados de 2,4-diaminopirimidina bíclica fusionada.
KR102377007B1 (ko) 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 융합 피리미딘 골격 설폰아마이드 유도체

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
X091 Application refused [patent]
AMND Amendment
X701 Decision to grant (after re-examination)
GRNT Written decision to grant